I just wrote an e-mail to investor relations contact Andrew Barber and asked him to consider including a detailed valuation for both companies including synergies brought to the table based on the reassessment reports for each Allkem project and the third party report of Kroll Associates Australia. They shouldn't expect shareholders to vote for a deal negotiated before April of this year without providing some kind of validation of the fair ownership ratio, or otherwise what is the purpose of the Kroll Associates report supposed to be? I am now waiting for a response and the brochure.Not that my vote would move the needle, but big investors of Allkem should be more interested what happens to their own capital than retail investors..A proper company valuation on each side is not a simple task but should be done nonetheless.
AKE Price at posting:
$10.27 Sentiment: Buy Disclosure: Held
